Mar 2023 $5 M No. 4 $2 to $10 million 1
GENEOS Therapeutics, Inc.: Raise no. 4, Mar 2023 × Investors in this round 1 investor had bought by the notice of Apr 13, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $10 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Niranjan Y. Sardesai · Executive Officer, Director Casey Y. Cunningham · Director James Y. Eadie · Director Laurent Y. Humeau · Director Samuel Y. Broder · Director Sangwoo Y. Lee · Director Ted Y. Fjallman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Niranjan Y. Sardesai, Chief Executive Officer. Newest notice filed Apr 13, 2023. Read the notice at the SEC .
equity SEC Mar 2022 $17 M No. 3 $10 to $50 million 9
GENEOS Therapeutics, Inc.: Raise no. 3, Mar 2022 × Investors in this round 9 investors had bought by the notice of Mar 28, 2022: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $17 M of $25 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Niranjan Sardesai · Executive Officer, Director Casey Cunningham · Director Eadie James · Director Joseph Kim · Director Samuel Broder · Director Sangwoo Lee · Director Ted Fjallman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Niranjan Y. Sardesai, Chief Executive Officer. Newest notice filed Mar 28, 2022. Read the notice at the SEC .
equity SEC Nov 2020 $10 M No. 2 $10 to $50 million 4
GENEOS Therapeutics, Inc.: Raise no. 2, Nov 2020 × Investors in this round 4 investors had bought by the notice of Nov 17, 2020: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $12 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Niranjan Y. Sardesai · Executive Officer, Director Casey Joseph Cunningham · Director J. Joseph Kim · Director James Y. Eadie · Director Samuel Joseph Broder · Director Sangwoo Joseph Lee · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Niranjan Y. Sardesai, President and Chief Executive Officer. Newest notice filed Nov 17, 2020. Read the notice at the SEC .
equity SEC Feb 2019 $5 M No. 1 $2 to $10 million 3
GENEOS Therapeutics, Inc.: Raise no. 1, Feb 2019 × Investors in this round 3 investors had bought by the notice of Feb 27, 2019: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $11 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, other: Warrants to purchase Common Stock will be issued to M.M. Dillon & Co. and designees of Brookline Capital Markets in addition to any fees paid for commissions and financial advice. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $50,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Niranjan Y. Sardesai · Executive Officer, Director Casey Y. Cunningham · Director J. Joseph Kim · Director James Y. Eadie · Director Samuel Y. Dr. Broder · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Angela C. Dong (CRD 4367592) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY John Dexter Pearson (CRD 6093501) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY Scott A. Katzmann (CRD 1087840) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY Harris R.L. Lydon Jr. (CRD 1796845) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY Graham A Powis (CRD 2420999) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY Samuel P. Wertheimer (CRD 5984076) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY M.M.Dillon & Co., LLC (CRD 19878) · broker-dealer M.M. Dillon & Co., LLC (CRD 19878) · Greenwich, Connecticut Sold in CT, NY William B. Buchanan, Jr. (CRD 1048722) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY Andrew D. Daniels (CRD 2251612) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New York Sold in CT, NY Remarks in the notice On fees: “In addition to $50,000, Brookline Capital Markets or its designees will be given Warrants to purchase common stock.”Signed by Niranjan Y. Sardesai, President and Chief Executive Officer. Newest notice filed Feb 27, 2019. Read the notice at the SEC .
equity, options SEC